Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics

“We are entering an increasingly important phase in Akari's evolution, as we translate the differentiated potential of our PH1 payload platform into a defined path toward clinical development”

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics

“The initiation of GLP toxicology studies represents a critical step toward bringing AKTX-101 into the clinic. Our latest preclinical findings provide further evidence of what we believe could be a meaningful competitive advantage of our unique ADC payload that disrupts RNA splicing: initial focus on treating the increasing number of patients refractory to current ADCs utilizing topoisomerase or microtubule inhibitor payloads, while subsequently, expanding the opportunity to be the first-line ADC of choice.”

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics

“The ADC landscape is rapidly evolving, and we believe the next wave of innovation will be driven not simply by new targets, but by novel payloads capable of overcoming the limitations of current treatments. That is precisely the opportunity we are pursuing with the PH1 payload”

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics

“With continued execution towards Phase 1 and unique collaborations as announced with Whitehawk Therapeutics, we believe Akari is increasingly well positioned to accelerate the value and impact of our differentiated ADC payload technology.”

Satyajit Mitra, Executive Director, Head of Oncology at Akari Therapeutics

“AKTX-101 showed encouraging activity in an advanced urothelial cancer model in which Padcev® had limited activity, and slowed tumor growth in a separate model after tumors developed resistance to Trodelvy®”

Satyajit Mitra, Executive Director, Head of Oncology at Akari Therapeutics

“Together, these findings support further evaluation of AKTX-101 after progression on prior ADC therapy. The Trodelvy® findings also reinforce our hypothesis that a different payload mechanism may help address payload-specific resistance while retaining the same TROP2 target.”